bioRxiv · 10.1101/2021.03.04.433987
Identifying Dihydropyrimidine Dehydrogenase as a Novel Regulator of Hepatic Steatosis
Abstract
Pyrimidine catabolism is implicated in hepatic steatosis. Dihydropyrimidine Dehydrogenase (DPYD) is an enzyme responsible for uracil and thymine catabolism, and DPYD human genetic variability affects clinically observed toxicity following 5-Fluorouracil (5-FU) administration. In an in vitro model of diet-induced steatosis, the pharmacologic inhibition of DPYD resulted in protection from lipid accumulation. Additionally, a gain-of-function mutation of DPYD, created through clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9) engineering, led to an increased lipid burden, which was associated with altered mitochondrial functionality in a hepatocarcionma cell line. The studies presented herein describe a novel role for DPYD in hepatocyte metabolic regulation as a modulator of hepatic steatosis.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Sullivan, K. E., Kumar, S., Zhang, Y., de Koning, E., Yuan, J., Fan, F.. 2021-03-04. Identifying Dihydropyrimidine Dehydrogenase as a Novel Regulator of Hepatic Steatosis. https://doi.org/10.1101/2021.03.04.433987
Cite the original work for its findings. Save a collection to share your selection of sources.